Drug Profile
ADx
Alternative Names: ADx 001; ADX-001; DSPE-DOTA-Gd Liposomal InjectionLatest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Alzeca Biosciences
- Class Antidementias; Contrast media; Hexosamines; Imaging agents; Macrocyclic compounds; Organometallic compounds; Phosphates; Radiopharmaceutical diagnostics
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 22 Aug 2022 Phase-I development is ongoing in Germany (NCT05453539)
- 11 Jul 2022 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in Germany (IV)(NCT05453539)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in USA